Skip to main
DRTS

DRTS Stock Forecast & Price Target

DRTS Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Alpha Tau Medical Ltd has recently achieved significant operational milestones, including receiving regulatory approval in Japan for its Alpha DaRT platform, which enhances the prospects for clinical development in the U.S. The company also secured a radioactive material license in New Hampshire and initiated construction of a commercial-scale manufacturing facility, positioning it for future manufacturing of Alpha DaRT beginning in 2026. The favorable cash position further supports its ongoing clinical programs targeting multiple solid tumor types, bolstering the potential for market success and revenue generation.

Bears say

Alpha Tau Medical Ltd reported a significant net loss of $42.6 million in 2025, reflecting ongoing financial challenges and a higher-than-anticipated loss per share of $0.53, which raises concerns about the company's financial sustainability. The company faces multiple risks that could impede its future success, including potential failures in clinical trials, difficulties in securing regulatory approval in the U.S., and challenges related to market penetration and competition for its Alpha DaRT technology. Additionally, there is a looming risk of dilution that may further impact shareholder value, contributing to a negative outlook on the stock.

DRTS has been analyzed by 3 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alpha Tau Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alpha Tau Medical (DRTS) Forecast

Analysts have given DRTS a Buy based on their latest research and market trends.

According to 3 analysts, DRTS has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alpha Tau Medical (DRTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.